Posted by Social Science Research Network
Three Challenges for Pharmaceutical Antitrust
By Michael A. Carrier (Rutgers Law School)
Pharmaceutical antitrust law is hard. When drug companies delay generic entry, is that beneficial “life-cycle management”? Or is it unjustified anti-competitive behavior? The question arises in multiple settings, including patent settlements by which brand firms pay generics to delay entering the market, product reformulations made to prevent generic adoption, citizen petitions filed with the U.S. Food and Drug Administration (FDA), and the denial of samples generics need to enter the market.
Courts confront challenges when addressing these complex questions. And sometimes, they veer astray. Why? This essay seeks to answer that question, cataloging three mistakes courts have made in this setting, which are based on (1) complexity, (2) simplicity, and (3) Sisyphus.
The first category emphasizes the unique complexity of the pharmaceutical industry. The second points out how courts have prioritized simplicity in the areas of pay-for-delay settlements (based on the policy favoring settlement and presumptive validity of patents) and “product hopping” (based on the number of products on the market and size of the generic).
The third category then analogizes the challenge to the mythological figure Sisyphus, who labored to push a boulder uphill, with any progress in inching the boulder up quickly followed by the boulder rolling back downhill. I highlight eight hurdles that tempt courts to let the boulder roll downhill when they are confronted with arguments taking the form of safety, product liability, immunity, innovation, the scope of the patent, risk aversion, patent validity, and assisting rivals.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI